Locoid, cream 0,1% 30 g

Lokoid is a synthetic nonhalogenated glucocorticosteroid for external use.

The esterification of the hydrocortisone molecule with an oily acid residue (butyrate) allowed to radically increase the activity of the drug compared to native hydrocortisone.

Lokoid has a rapid onset anti-inflammatory, anti-edema, antipruritic effect.
The use of Lokoid in the recommended doses does not cause suppression of the hypothalamic-pituitary-adrenal system.

While use of high doses of the drug for long periods of time, especially with occlusive dressings, may lead to an increase in plasma cortisol levels, this is not usually accompanied by a decrease in pituitary-adrenal reactivity, and withdrawal of the drug leads to rapid normalization of cortisol production.

Pharmacokinetics:

After application, the active substance accumulates in the epidermis, mainly in the granular layer, with little systemic absorption. A small amount of hydrocortisone 17-butyrate is absorbed into the systemic bloodstream unchanged.

The majority of hydrocortisone 17-butyrate is metabolized to hydrocortisone and other metabolites directly in the epidermis and subsequently in the liver.

Metabolites and a small portion of unchanged hydrocortisone 17-butyrate are excreted by the kidneys and through the intestine.

Indications

Superficial, non-infectious, sensitive to local glucocorticosteroids skin diseases:
– dermatitis, including atopic, contact, seborrheic;
– eczema;
– psoriasis.

Active ingredient

Composition

The cream for external use is white and homogeneous.

1 g hydrocortisone butyrate 1 mg

Supplementary substances:

cetostearyl alcohol 72 mg,

macrogol 25 cetostearyl ether 18 mg,

liquid paraffin 60 mg,

/p>

white soft paraffin 150 mg,

propyl parahydroxybenzoate 1 mg,

butyl parahydroxybenzoate 0.5 mg,

citric acid anhydrous 4.2 mg,

sodium citrate anhydrous 2.8 mg,

purified water to 1 g.

How to take, the dosage

Externally.

Lokoid cream is preferably used in acute and subacute skin processes (without mucous membrane).

The drug is applied to the affected areas of the skin in a thin layer 1-3 times a day. To improve penetration the drug is applied with light massaging movements. If there is positive response the frequency of application can be reduced to 2-3 times a week.

The dose of the drug used in a week should not exceed 30-60 g.

Special Instructions

Possible to use in children from 6 months of age. If the drug is used in children, on the face area or under occlusive dressings, the duration of treatment should be reduced.

When used in children, the surface area of the skin to which the drug is applied should not exceed 20% of the total.

In children, suppression of adrenal cortical function may develop more rapidly. In addition, a decrease in growth hormone excretion may be observed. When using the drug for a long time, body weight, growth, and plasma cortisol levels should be monitored.

In a study in children who received 30-60 g of Locoid per week for 4 weeks compared to 1% hydrocortisone ointment, no child showed abnormal adrenal cortical function, with no difference between hydrocortisone 17-butyrate and regular hydrocortisone on this index.

Locoid should not be applied to the periorbital area because of the risk of glaucoma. There is a risk of increased intraocular pressure if there is systemic contact with the conjunctiva.

In case of localization of the process on the scalp and exudative inflammation, Locoid in Crelo form is preferred.

In cases of resistant disease, such as localization of dense psoriatic plaques on the elbows and knees, marked lichenification and dryness, preference should be given to Lokoid in ointment or Lipokrem form, if necessary under occlusive dressings.

The drug is not advisable for use in the presence of atrophic skin changes. The risk of local and systemic side effects increases with application to large areas of lesions, prolonged use, use of occlusions and in children.

If there is no effect within 2 weeks of continuous treatment, the diagnosis should be clarified.

As with any glucocorticosteroid medication, it is advisable to limit the duration of use and the course dose to the minimum sufficient to stop the skin process.

Impact on the ability to drive vehicles and operate machinery:

There are no data on the effect of Lokoid on the ability to drive and operate machinery.

Contraindications

– Hypersensitivity to hydrocortisone or auxiliary components of the drug;
– bacterial skin infections (strepto- and staphyloderma, gram-negative folliculitis etc.);
– viral skin infections (herpes simplex, varicella, herpes zoster etc.)
– skin fungal infections;
– tuberculosis and syphilitic skin affections;
– parasitic skin infections;
– neoplastic skin changes (benign and malignant tumors);
– acne, rosacea, perioral dermatitis;
– postvaccination period;
– skin integrity disorders (wounds, ulcers).

With caution: pregnancy, lactation.

Side effects

Local reactions: skin irritation, in rare cases – other local reactions typical for external steroid therapy.

Systemic reactions: with long-term use, application on large surfaces and/or use of occlusion, side effects characteristic of systemic glucocorticosteroids may be observed.

The risk of local and systemic side effects with Locoid is lower than with fluorinated steroids.

Overdose

There are no data on overdose of Locoid.

Long-term use of the drug in high doses may increase the above side effects.

In case of symptoms of hypercorticism the drug should be discontinued.

Pregnancy use

Similarities